Compare ARWR & CRL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ARWR | CRL |
|---|---|---|
| Founded | 2003 | 1947 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Commercial Physical & Biological Resarch |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 10.1B | 8.3B |
| IPO Year | 2009 | 1999 |
| Metric | ARWR | CRL |
|---|---|---|
| Price | $64.60 | $178.50 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 10 | 13 |
| Target Price | $81.50 | ★ $197.58 |
| AVG Volume (30 Days) | ★ 2.7M | 1.3M |
| Earning Date | 05-08-2026 | 05-19-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 99.80 | N/A |
| EPS | ★ 0.22 | N/A |
| Revenue | $16,142,321.00 | ★ $1,857,601,000.00 |
| Revenue This Year | N/A | $2.51 |
| Revenue Next Year | N/A | $4.66 |
| P/E Ratio | $287.41 | ★ N/A |
| Revenue Growth | N/A | ★ 10.48 |
| 52 Week Low | $10.66 | $91.86 |
| 52 Week High | $76.76 | $228.88 |
| Indicator | ARWR | CRL |
|---|---|---|
| Relative Strength Index (RSI) | 51.54 | 46.92 |
| Support Level | $60.53 | $145.97 |
| Resistance Level | $65.59 | $182.81 |
| Average True Range (ATR) | 2.68 | 9.73 |
| MACD | 0.01 | 1.99 |
| Stochastic Oscillator | 87.05 | 84.10 |
Arrowhead Pharmaceuticals Inc is an American biotechnology company. Its main target is the development of medicine to treat diseases with a genetic origin, characterized by the overproduction of one or more proteins. Its medical solutions are aimed at the genes that trigger the diseases. Its portfolio includes drugs targeting cardiovascular, Cardiometabolic, Central Nervous System, Pulmonary, Liver, Muscular, and Complement Mediated Disease. It majority products are liver disease curable.
Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company's research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provides in vitro (non-animal) testing products, biologics testing services, and avian vaccine services.